ARA-290: Community Protocols & Reports
Aggregated community experiences, protocols, and stacking patterns
Community-Sourced Information
The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.
For peer-reviewed dosing protocols, see the clinical dosing guide.
Browse community protocols for all 130 peptides โ
๐TL;DR
- โข2 community protocols documented
- โขEvidence level: Anecdotal Reports
- โขBased on 15 community reports
- โข2 stacking patterns reported
Clinical vs. Community Protocol Differences
How community-reported protocols differ from clinical research protocols.
| Aspect | Clinical Approach | Community Approach | Significance |
|---|---|---|---|
| Availability | ARA-290 (cibinetide) has been used in multiple Phase 2 clinical trials at doses of 2-4 mg daily subcutaneous injection for sarcoidosis-related neuropathy and small fiber neuropathy. | ARA-290 is extremely difficult to obtain outside of clinical trials. Very few peptide vendors carry it, and community usage reports are correspondingly rare. | high The limited availability of ARA-290 means community protocol data is minimal compared to more accessible peptides like BPC-157 or Selank. |
| Dosing | Clinical trials used fixed doses of 2 mg or 4 mg daily SC injection, with some studies using 3 times weekly dosing for 28 days. | The few community reports available generally follow clinical trial dosing (2-4 mg daily), as there is insufficient user data to establish community-derived protocols. | low Unlike many research peptides where community dosing diverges significantly from clinical protocols, ARA-290 users tend to follow published trial dosing. |
| Indication | Clinical trials focused on sarcoidosis-related neuropathy, diabetic neuropathy, and small fiber neuropathy with objective nerve fiber density measurements. | Community interest extends beyond neuropathy to general neuroprotection, post-injury neural recovery, and as part of broader healing stacks. | moderate Community use cases are broader than the studied indications, though evidence for these expanded applications is limited. |
Compare these community approaches with published research findings.
Community Protocols
Standard Neuropathy Protocol
Niche- Route
- Subcutaneous
- Dose
- 2-4 mg
- Frequency
- Once daily
- Duration
- 28-84 days
Based on clinical trial dosing; very few community users report self-administering ARA-290 due to limited availability
Low-Dose Neuroprotective Protocol
Niche- Route
- Subcutaneous
- Dose
- 1-2 mg
- Frequency
- Once daily
- Duration
- 4-8 weeks
Some community members report using lower doses for general neuroprotective purposes
Stacking Patterns
ARA-290 + BPC-157 Neuroprotective Stack
NicheCombined neuroprotection and tissue healing; ARA-290 for nerve repair via innate repair receptor activation and BPC-157 for broader tissue healing
Check stack compatibility and review potential side effects before combining peptides.
Unlock community dosing protocols and stacking combos
See the exact doses, routes, and schedules 15+ self-experimenters report. Free with email.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Sources
- Reddit r/Peptides|ARA-290 / Cibinetide discussion threads(accessed 2026-02-16)
- Reddit r/PeptideResearch|ARA-290 research and mechanism discussions(accessed 2026-02-16)
- Longecity Forum|ARA-290 neuroprotection discussions(accessed 2026-02-16)
Community Evidence Overview#
ARA-290 (cibinetide) has very limited community usage data. Unlike widely available research peptides such as BPC-157, TB-500, or Selank, ARA-290 remains difficult to source outside of clinical trial settings. This page documents the limited community discussion and protocols that exist, but readers should note that the evidence base for self-experimentation with ARA-290 is minimal.
This page presents community-sourced information and is not clinical evidence. It should not be used as medical guidance.
The community interest in ARA-290 is driven primarily by its novel mechanism of action โ selective activation of the innate repair receptor (IRR), an EPO receptor heteromer that mediates tissue protection without stimulating red blood cell production. Multiple Phase 2 clinical trials have demonstrated potential in sarcoidosis-related neuropathy, but community access remains limited.
Protocol Divergence#
Availability Gap#
The most significant factor shaping community protocols for ARA-290 is availability. Unlike peptides that are widely sold by research chemical vendors, ARA-290 is rarely stocked, and when available, tends to be expensive. This means:
- Community protocol data is based on very few reports
- Most "protocols" discussed in forums are theoretical, based on published clinical trial designs
- There is no established community dosing consensus independent of clinical research
Dosing Alignment#
Unusually for a research peptide, the few community users who have tried ARA-290 tend to follow clinical trial dosing (2-4 mg daily SC) rather than developing divergent community protocols. This is likely because:
- The peptide is too niche for extensive dose-finding by self-experimenters
- Clinical trial data provides clear dosing guidance
- The cost of the peptide discourages experimentation with higher doses
Commonly Reported Outcomes#
Due to the very limited number of community reports, outcomes data should be interpreted with extreme caution:
- Neuropathy symptoms: A small number of users with diagnosed neuropathies have reported modest improvements in nerve-related symptoms
- General neuroprotection: Some users report subjective cognitive and nerve function improvements, though these are difficult to distinguish from placebo
- Tolerability: Reports consistently describe ARA-290 as well-tolerated with minimal side effects, consistent with clinical trial safety data
Important Caveats#
- The number of community reports is extremely small (estimated <20 total)
- No community consensus exists on efficacy outside of clinical trial contexts
- Product authenticity is a significant concern given the peptide's rarity
- Self-reported neuropathy improvements are difficult to verify without clinical assessment
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Frequently Asked Questions About ARA-290
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.